"There will not be any research funded by NIH on mRNA vaccines," the scientist in New York similarly told the outlet. "MAGA ...

Scientists in the US who do research on mRNA technology worry their funding may be cut under President Trump. mRNA technology is the basis for COVID- and other vaccines and could play a role in cancer ...

Total company revenue fell from a peak of $19.3 billion in 2022 to $3.2 billion for the full year ended Dec. 31, 2024. For ...

Shares of Moderna, Inc. (NASDAQ:MRNA – Get Free Report) have been assigned an average rating of “Hold” from the twenty-four ...

As we previously discussed, beginning in 2022, a series of patent infringement lawsuits were filed against Moderna and ...

Scientists say that officials from the National Institutes of Health urged them to remove references to mRNA vaccine ...

Moderna (NASDAQ: MRNA), and Pfizer (NYSE: PFE) are dirt cheap now, and why buying these value stocks could be a brilliant ...

Moderna (NASDAQ:MRNA – Get Free Report) had its price objective lowered by analysts at JPMorgan Chase & Co. from $40.00 to ...

A handful of states are targeting the technology at the same time the Trump administration is cutting research funding and ...

Bloomberg reported late last month that Trump administration health officials were reevaluating a $590 million contract for ...

The door may now be open for additional challenges to patents covering mRNA vaccine technologies, paving the way for increased competition in the ...

Yet vaccines using the new technology of mRNA were developed by Moderna and Pfizer/BioNTech in a matter of months, and were already being put into arms by the first anniversary of the pandemic.